Candriam S.C.A. Xenon Pharmaceuticals Inc. Transaction History
Candriam S.C.A.
- $16.9 Billion
- Q4 2024
A detailed history of Candriam S.C.A. transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 492,181 shares of XENE stock, worth $19.6 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
492,181
Previous 463,861
6.11%
Holding current value
$19.6 Million
Previous $18.3 Million
5.7%
% of portfolio
0.11%
Previous 0.11%
Shares
14 transactions
Others Institutions Holding XENE
# of Institutions
219Shares Held
70.4MCall Options Held
109KPut Options Held
2.1K-
Avoro Capital Advisors LLC New York, NY5.67MShares$225 Million3.24% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.52MShares$180 Million1.73% of portfolio
-
Wellington Management Group LLP Boston, MA3.78MShares$150 Million0.03% of portfolio
-
Braidwell LP Stamford, CT2.91MShares$116 Million6.4% of portfolio
-
Janus Henderson Group PLC London, X02.87MShares$114 Million0.06% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.47B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...